AIO-Studien-gGmbH

Quick facts

Phase 2 pipeline

• catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel
• Chemotherapy by Investigator's choice
• Epirubicin, Cisplatin, Capecitabine, Panitumumab
  Combines DNA-damaging chemotherapy agents with EGFR inhibition to attack cancer cells through multiple pathways.
• Fluorouracil, leucovorin, oxaliplatin, docetaxel
• FOLFIFINOX · Oncology
  FOLFIRINOX is a chemotherapy regimen that combines four different drugs to target rapidly dividing cancer cells.
• S-1 de-escalation
• Vinorebine, Everolimus

Phase 1 pipeline

• nintedanib-nivolumab combination therapy

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• AIO-Studien-gGmbH portfolio CI brief
• AIO-Studien-gGmbH pipeline updates RSS

Related

• Sector hub: All tracked pharma companies